Literature DB >> 19142111

Does the length of the first antidepressant treatment episode influence risk and time to a second episode?

Helga Gardarsdottir1, Erica C G van Geffen, Joost J Stolker, Toine C G Egberts, Eibert R Heerdink.   

Abstract

Antidepressant treatment in primary care is inconsistent with treatment recommendations, and many patients discontinue treatment within 6 months. How this affects treatment outcomes is unknown. The aim of this study was to assess how length of the first antidepressant episode influences risk and time to a second treatment episode within 5 years.The study population included 9423 adults (67% women; mean age, 47.3 years) who initiated selective serotonin reuptake inhibitor use in 1998 or 1999. Based on the length of the first antidepressant treatment episode, patients were divided into early discontinuers (<6 months), continuing users (6-12 months), and persistent users (>12 months). The Cox proportional hazards model was used to estimate risk ratios (RRs) for the association between the length of the first antidepressant treatment episode and time to reinitiating antidepressant treatment.Time to a second treatment episode did not differ significantly between continuing users and early discontinuers (RR, 0.99; 95% confidence interval, 0.92-1.07). Persistent users showed a higher risk of experiencing a second treatment episode than early discontinuers (RR, 1.23; 95% confidence interval, 1.15-1.32).In conclusion, the risk of experiencing a second antidepressant treatment episode did not differ for those who used antidepressants for 6 to 12 months and those who discontinued early. In general, there is limited information on how length of an antidepressant treatment episode influences the risk of reinitiating treatment of patients in primary care. More research is needed to investigate the effectiveness of antidepressant drug treatment patterns in preventing relapse or recurrence in primary care populations.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19142111     DOI: 10.1097/JCP.0b013e31819302b1

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN: 0271-0749            Impact factor:   3.153


  7 in total

1.  Methods for constructing treatment episodes and impact on exposure-outcome associations.

Authors:  Laura Pazzagli; Lena Brandt; Marie Linder; David Myers; Panagiotis Mavros; Morten Andersen; Shahram Bahmanyar
Journal:  Eur J Clin Pharmacol       Date:  2019-11-22       Impact factor: 2.953

2.  Antidepressant utilization patterns and mortality in Swedish men and women aged 20-34 years.

Authors:  Karolina Andersson Sundell; Mika Gissler; Max Petzold; Margda Waern
Journal:  Eur J Clin Pharmacol       Date:  2010-11-10       Impact factor: 2.953

3.  Treatment duration with selective serotonin reuptake inhibitors among children and adolescents in Finland: a nationwide register study.

Authors:  Leena K Saastamoinen; Mika Wallin; Piia Lavikainen; Marja S Airaksinen; Andre Sourander; J Simon Bell
Journal:  Eur J Clin Pharmacol       Date:  2012-02-12       Impact factor: 2.953

Review 4.  Methods for time-varying exposure related problems in pharmacoepidemiology: An overview.

Authors:  Laura Pazzagli; Marie Linder; Mingliang Zhang; Emese Vago; Paul Stang; David Myers; Morten Andersen; Shahram Bahmanyar
Journal:  Pharmacoepidemiol Drug Saf       Date:  2017-12-28       Impact factor: 2.890

Review 5.  How effective are antidepressants for depression over the long term? A critical review of relapse prevention trials and the issue of withdrawal confounding.

Authors:  Michael P Hengartner
Journal:  Ther Adv Psychopharmacol       Date:  2020-05-08

6.  Outcomes associated with antidepressant treatment according to the number of prescriptions and treatment changes: 5-year follow-up of a nation-wide cohort study.

Authors:  Charles Ouazana-Vedrines; Thomas Lesuffleur; Anne Cuerq; Anne Fagot-Campagna; Antoine Rachas; Chrystelle Gastaldi-Ménager; Nicolas Hoertel; Frédéric Limosin; Cédric Lemogne; Philippe Tuppin
Journal:  Front Psychiatry       Date:  2022-09-08       Impact factor: 5.435

Review 7.  Risk of relapse after antidepressant discontinuation in anxiety disorders, obsessive-compulsive disorder, and post-traumatic stress disorder: systematic review and meta-analysis of relapse prevention trials.

Authors:  Neeltje M Batelaan; Renske C Bosman; Anna Muntingh; Willemijn D Scholten; Klaas M Huijbregts; Anton J L M van Balkom
Journal:  BMJ       Date:  2017-09-13
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.